Copyright © Inderes 2011 - present. All rights reserved.
Log ind for at modtage meddelelser.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Lipidor

0,303

 

SEK

 

+0,66 %

Mindre end 1K følgere

LIPI

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
+0,66%
+15,65%
-5,31%
+42,25%
+125,28%
+413,32%
-80,69%
-89,43%
-82,86%

Lipidor is a pharmaceutical company. The company works with research and development in the preclinical and clinical phases. The largest business is established in the development of pharmaceuticals that are further used for the treatment of various skin diseases. Examples of diseases that are treated include psoriasis, various skin infections, and atopic dermatitis. The head office is located in Solna.

Læs mere
Markedsværdi
246,46 mio. SEK
Aktieomsætning
1,59 mio. SEK
Omsætning
10 t
EBIT %
-142.100 %
P/E
-
Udbytteafkast, %
-
Finanskalender
3.6
2025

Generalforsamling '25

28.8
2025

Delårsrapport Q2'25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse9.5.2025, 12.25

Lipidor AB (publ) publishes annual report for 2024

Lipidor
Pressemeddelelse17.3.2025, 07.30

Lipidor announces all patients enrolled in ongoing Phase III study

Lipidor
Selskabsmeddelelse28.2.2025, 07.30

Lipidor AB (publ) publishes year-end report for 2024

Lipidor

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pressemeddelelse21.1.2025, 07.00

Lipidor announces half of patients enrolled in ongoing Phase III study

Lipidor
Selskabsmeddelelse3.12.2024, 07.00

Lipidor presents Nomination Committee

Lipidor
Pressemeddelelse20.11.2024, 07.00

Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025"

Lipidor
Pressemeddelelse24.9.2024, 16.30

Lipidor announces first patient enrolled in Phase III study of AKP02G2 for topical treatment of psoriasis

Lipidor
Selskabsmeddelelse28.8.2024, 06.30

Lipidor AB (publ) publishes interim report for Q2 2024

Lipidor
Pressemeddelelse20.8.2024, 11.50

Lipidor announces that clinical trial material for psoriasis candidate AKP02G2 has been released according to plan

Lipidor
Selskabsmeddelelse1.7.2024, 06.15

Lipidor resolves on a directed issue of shares to underwriters in connection with the completion of the rights issue

Lipidor
Selskabsmeddelelse25.6.2024, 19.57

Lipidor's rights issue and share capital reduction are registered – conversion of BTU into shares and warrants

Lipidor
Selskabsmeddelelse13.6.2024, 18.46

Lipidor announces final outcome in the rights issue

Lipidor
Selskabsmeddelelse12.6.2024, 18.58

Lipidor announces preliminary outcome in the rights issue

Lipidor
Selskabsmeddelelse7.6.2024, 06.30

Last day of trading in unit rights in Lipidor's rights issue

Lipidor
Selskabsmeddelelse5.6.2024, 08.00

Bulletin from the Annual General Meeting of Lipidor AB (publ)

Lipidor
Selskabsmeddelelse29.5.2024, 06.30

Lipidor invites to digital presentations with Q&A

Lipidor
Selskabsmeddelelse29.5.2024, 06.00

Today the subscription period in Lipidor's rights issue begins

Lipidor
Selskabsmeddelelse24.5.2024, 10.21

Lipidor publishes prospectus due to upcoming rights issue of units

Lipidor
Selskabsmeddelelse22.5.2024, 06.30

Lipidor AB (publ) publishes interim report for Q1 2024

Lipidor
Selskabsmeddelelse21.5.2024, 09.40

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

Lipidor
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team